PI3Kγ in hypertension: A novel therapeutic target controlling vascular myogenic tone and target organ damage

Cardiovascular Research

Volumn 95, Issue 4, 2012, Pages 403-408

  Carnevale, Daniela ^a   Lembo, Giuseppe ^a  

^a IRCCS NEUROMED   (Italy)

Author keywords

Cell signalling; Inflammation; Myogenic tone; Phosphoinositide 3 kinase ; Signal transduction

Indexed keywords

5 (6 QUINOXALINYLMETHYLENE) 2,4 THIAZOLIDINEDIONE; 5 [5 (4 FLUORO 2 HYDROXYPHENYL)FURFURYLIDENE] 2,4 THIAZOLIDINEDIONE; ANGIOTENSIN II; BETA ADRENERGIC RECEPTOR; CALCIUM CHANNEL; CALCIUM CHANNEL L TYPE; CYCLIC AMP; G PROTEIN COUPLED RECEPTOR; GE 21; ISOENZYME; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; RAS PROTEIN; UNCLASSIFIED DRUG;

ADRENERGIC STIMULATION; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CALCIUM TRANSPORT; DISEASE COURSE; DRUG TARGETING; ENVIRONMENTAL STRESS; ENZYME ACTIVITY; ENZYME STRUCTURE; ENZYME SUBUNIT; GENETIC ASSOCIATION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE NECROSIS; HUMAN; HYPERTENSION; IMMUNE DEFICIENCY; INTRACELLULAR SIGNALING; LUPUS ERYTHEMATOSUS NEPHRITIS; MEAN ARTERIAL PRESSURE; MECHANOTRANSDUCTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULSE PRESSURE; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SMOOTH MUSCLE FIBER; SYSTEMIC LUPUS ERYTHEMATOSUS; VASOCONSTRICTION; VASODILATATION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ARTERIAL PRESSURE; CALCIUM CHANNELS, L-TYPE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTENSION; MUSCLE, SMOOTH, VASCULAR; PHENOTYPE; PHOSPHATIDYLINOSITOL 3-KINASE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 84865275725     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvs166     Document Type: Review

References (48)

1. MacMahon S. Blood pressure and the risk of cardiovascular disease. N Eng J Med 2000; 342:50-52.
2. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 2007;204:2449-2460.
3. Tang KM, Wang GR, Lu P, Karas RH, Aronovitz M, Heximer SP et al. Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure. Nat Med 2003;9:1506-1512.
4. Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 1995;377: 239-242.
5. Sonoyama K, Greenstein A, Price A, Khavandi K, Heagerty T. Vascular remodeling: implications for small artery function and target organ damage. Ther Adv Cardiovasc Dis 2007;1:129-137.
6. Hill MA, Meininger GA, Davis MJ, Laher I. Therapeutic potential of pharmacologically targeting arteriolar myogenic tone. Trends Pharmacol Sci 2009;30:363-374.
7. Yamazaki D, Tabara Y, Kita S, Hanada H, Komazaki S, Naitou D et al. TRIC-A channels in vascular smooth muscle contribute to blood pressure maintenance. Cell Metab 2011;14:231-241.
8. Bergaya S, Faure S, Baudrie V, Rio M, Escoubet B, Bonnin P et al. WNK1 regulates vasoconstriction and blood pressure response to a1-adrenergic stimulation in mice. Hypertension 2011;58:439-445.
9. Osol G, Brekke JF, McElroy-Yaggy K, Gokina NI. Myogenic tone, reactivity, and forced dilatation: a three-phase model of in vitro arterial myogenic behavior. Am J Physiol Heart Circ Physiol 2002;283:H2260-H2267.
10. Hill MA, Davis MJ, Meininger GA, Potocnik SJ, Murphy TV. Arteriolar myogenic signalling mechanisms: implications for local vascular function. Clin Hemorheol Microcirc 2006;34:67-79.
11. Wain LV, Verwoert GC, O'Reilly PF, Shi G, Johnson T, Johnson AD et al. Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. Nat Genet 2011;43:1005-1011.
12. Carnevale D, Vecchione C, Mascio G, Esposito G, Cifelli G, Martinello K et al. PI3Kg inhibition reduces blood pressure by a vasorelaxant Akt/L-type calcium channel mechanism. Cardiovasc Res 2012;93:200-209.
13. Vecchione C, Patrucco E, Marino G, Barberis L, Poulet R, Aretini A et al. Protection from angiotensin II-mediated vasculotoxic and hypertensive response in mice lacking PI3Kg. J Exp Med 2005;201:1217-1228.
14. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002;296:1655-1657.
15. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signaling. Nat Rev Mol Cell Biol 2010;11:329-341.
16. Kok K, Geering B, Vanhaesebroeck B. Regulation of phosphoinositide 3-kinase expression in health and disease. Trends Biochem Sci 2009;34:115-127.
17. Oudit GY, Sun H, Kerfant BG, Crackower MA, Penninger JM, Backx PH. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J Mol Cell Cardiol 2004;37:449-471.
18. Morello M, Perino A, Hirsch E. Phosphoinositide 3-kinase signalling in the vascular system. Cardiovasc Res 2009;82:261-271.
19. Shiojima I, Walsh K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ Res 2002;90:1243-1250.
20. Hirsch E, Ciraolo E, Ghigo A, Costa C. Taming the PI3K team to hold inflammation and cancer at bay. Pharmacol Ther 2008;118:192-205.
21. Oudit GY, Penninger JM. Cardiac regulation by phosphoinositide 3-kinases and PTEN. Cardiovasc Res 2009;82:250-260.
22. Harris SJ, Parry RV, Westwick J, Ward SG. Phosphoinositide lipid phosphatases: natural regulators of phosphoinositide 3-kinase signaling in T lymphocytes. J Biol Chem 2008;283:2465-2469.
23. Maehama T, Taylor GS, Dixon JE. PTEN and myotubularin: novel phosphoinositide phosphatases. Annu Rev Biochem 2001;70:247-279.
24. Rohrschneider LR, Fuller JF, Wolf I, Liu Y, Lucas DM. Structure, function, and biology of SHIP proteins. Genes Dev 2000;14:505-520.
25. House SJ, Potier M, Bisaillon J, Singer HA, Trebak M. The non-excitable smooth muscle: calcium signaling and phenotypic switching during vascular disease. Pflugers Arch 2008;456:769-785.
26. 2+ signaling, cell activation and cell survival in immune cells. Mol Immunol 2010;47: 640-648.
27. Crackower MA, Oudit GY, Kozieradzki I, Sarao R, Sun H, Sasaki T et al. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell 2002;110:737-749.
28. Naga Prasad SV, Esposito G, Mao L, Koch WJ, Rockman HA. Gbg-dependent phos-phoinositide 3-kinase activation in hearts with in vivo pressure overload hypertrophy. J Biol Chem 2000;275:4693-4698.
29. Oudit GY, Crackower MA, Eriksson U, Sarao R, Kozieradzki I, Sasaki T et al. Phos-phoinositide 3-kinase g-deficient mice are protected from isoproterenol-induced heart failure. Circulation 2003;108:2147-2152.
30. Patrucco E, Notte A, Barberis L, Selvetella G, Maffei A, Brancaccio M et al. PI3Kg modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and-independent effects. Cell 2004;118:375-387.
31. Perino A, Ghigo A, Ferrero E, Morello F, Santulli G, Baillie GS et al. Integrating cardiac PIP3 and cAMP signaling through a PKA anchoring function of p110g. Mol Cell 2011; 42:84-95.
32. Damilano F, Franco I, Perrino C, Schaefer K, Azzolino O, Carnevale D et al. Distinct effects of leukocyte and cardiac phosphoinositide 3-kinase g activity in pressure overload-induced cardiac failure. Circulation 2011;123:391-399.
33. 2+ channels via phosphoinositide 3-kinase. FASEB J 1999;13: 685-694.
34. Quignard JF, Mironneau J, Carricaburu V, Fournier B, Babich A, Nurnberg B et al. Phosphoinositide 3-kinase g mediates angiotensin II-induced stimulation of L-type calcium channels in vascular myocytes. J Biol Chem 2001;276:32545-32551.
35. 2+ channels. Circ Res 2001;89:692-699.
36. 2+ channels by phosphatidylinositol 3, 4, 5-trisphosphate. Circ Res 2004;95:300-307.
37. Viard P, Butcher AJ, Halet G, Davies A, Nürnberg B, Heblich F et al. PI3K promotes voltage-dependent calcium channel trafficking to the plasma membrane. Nat Neurosci 2004;7:939-946.
38. 2+ channel activity by modulating Cava1 protein stability. J Cell Biol 2009;184:923-933.
39. 2+ sensitivity regulation in promoting myogenic vasoconstriction. Cardiovasc Res 2008;77:8-18.
40. Patel A, Sharif-Naeini R, Folgering JR, Bichet D, Duprat F, Honoré E. Canonical TRP channels and mechanotransduction: from physiology to disease states. Pflugers Arch 2010;460:571-581.
41. Camps M, Rückle T, Ji H, Ardissone V, Rintelen F, Shaw J et al. Blockade of PI3Kg suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med 2005;11:936-943.
42. Barber DF, Bartolomé A, Hernandez C, Flores JM, Redondo C, Fernandez-Arias C et al. PI3Kg inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat Med 2005;11:933-935.
43. Doukas J, Wrasidlo W, Noronha G, Dneprovskaia E, Fine R, Weis S et al. Phosphoi-nositide 3-kinase g/d inhibition limits infarct size after myocardial ischemia/reperfu-sion injury. Proc Natl Acad Sci USA 2006;103:19866-19871.
44. Siragusa M, Katare R, Meloni M, Damilano F, Hirsch E, Emanueli C et al. Involvement of phosphoinositide 3-kinase g in angiogenesis and healing of experimental myocar-dial infarction in mice. Circ Res 2010;106:757-768.
45. Fougerat A, Gayral S, Gourdy P, Schambourg A, Rückle T, Schwarz MK et al. Genetic and pharmacological targeting of phosphoinositide 3-kinase-g reduces atherosclerosis and favors plaque stability by modulating inflammatory processes. Circulation 2008; 117:1310-1317.
46. Cohuet G, Struijker-Boudier H. Mechanisms of target organ damage caused by hypertension: therapeutic potential. Pharmacol Ther 2006;111:81-98.
47. Chan AT, Manson JE, Albert CM, Chae CU, Rexrode KM, Curhan GC et al. Nonster-oidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 2006;113:1578-1587.
48. Brophy JM. Cardiovascular risk associated with celecoxib. N Engl J Med 2005;352: 2648-2650.